MintNeuro, a British semiconductor company building specialised chips for neural devices from implants to wearables, today announces a €4.4 million ($5 million) round to accelerate product launch, expand delivery of pre-release silicon to partners and grow the company’s international presence.
The round was led by Odyssey Ventures, with participation from 33East, JSK Investments and Alumni Ventures, and returning investment from Empirical Ventures, Jumpspace Ventures and early investors.
Commenting on the investment, Dorian Haci, co-founder and CEO of MintNeuro, says: “Every neural device depends on the chips inside it. Today, most device and therapy developers still have to choose between generic components that were never designed for the body and years of custom chip development.
“We are building the chips that end that trade-off. This funding moves us from technology validation to commercial scale-up, with more customer programmes, faster product launches and our chips in the hands of many more developers. Our ambition is clear: to make MintNeuro the semiconductor platform the global neurotechnology industry builds on.”
MintNeuro’s financing comes amid continued investment in European neurotechnology and neural-device infrastructure in 2026.
EU-Startups has reported €40.6 million for Eindhoven-based ONWARD Medical to advance spinal-cord stimulation technologies, €20 million for Vienna’s nyra health to expand its digital neurorehabilitation platform, €10 million for French-Belgian neurodiagnostics company neuroClues, and €4.3 million for UK-based Cerca Magnetics to scale its wearable brain-imaging technology.
Earlier-stage activity includes €1.7 million for Zurich- and London-based Connectome and €1.3 million for Amsterdam neuroprosthetics developer Phosphoenix, while adjacent semiconductor-enabled health hardware includes Lausanne-based Xsensio’s €6 million Series A.
Together, these 2026 rounds amount to approximately €83.9 million, rising to around €88.3 million when MintNeuro’s €4.4 million financing is included, with Cerca Magnetics and Connectome also providing UK-linked examples of investment in brain and neural technology.
Michelle Robson, Founding Partner at Odyssey Ventures, adds: “Neural devices such as BCIs represent one of the most exciting frontier technology opportunities today, and significant value will accrue to those solving the foundational infrastructure challenges that stand between innovation and widespread adoption.
“MintNeuro has the technology, market pull and ambition to become a globally important semiconductor company, and we are backing this exceptional team as it scales from the UK into global markets, including Silicon Valley.”
Founded in 2022 as a spinout from Imperial College London, MintNeuro is building the semiconductor foundation for the next generation of neurotechnology. The company develops specialised chips that enable devices to connect with the brain and nervous system, helping innovators create new therapies for neurological and mental health conditions.
The chips reportedly give device developers better performance than generic components, with less risk, lower cost and a faster route to market than custom chip design.
The company has already delivered working silicon and reached key integration milestones with research and development partners, including Motif Neurotech and Amber Therapeutics.
Earlier this year, MintNeuro announced a partnership and multi-year commercial chip supply agreement with Motif, supporting the development of Motif’s minimally invasive neurostimulator initially targeting treatment-resistant depression.
Yiannis Eftychiou, co-founder and Partner at 33East, says: “What stood out to us is the sheer breadth of the hardware opportunity. MintNeuro is solving critical needs for neural implants today, with technology that can extend into wearables and beyond.”
Neural devices are opening new ways to understand and treat conditions across neurology, mental health and beyond, from Parkinson’s disease, epilepsy and depression to hearing loss and inflammatory disease. These technologies include brain-computer interfaces (BCIs), neuromodulation systems, sensory prostheses and bioelectronic medicines.
Until now, the company says progress across the industry has been held back by the lack of standard chips designed specifically for the extreme power, size, safety and signal-quality demands of these devices.
MintNeuro looks to close that gap with a modular semiconductor platform purpose-built for core functions like neural sensing, signal processing and stimulation: listening to the body’s nerve signals, interpreting them, and delivering precise electrical pulses to treat disease or restore function.
Instead of adapting generic components or funding years of custom chip design, developers can build on MintNeuro’s chips to create smaller, lower-power neural devices and move from research to clinical use sooner.
Johnathan Matlock, co-founder and General Partner at Empirical Ventures, says: “We invested before the chips were in hand, and we are reinvesting now that MintNeuro has working silicon, deep customer traction and a clear path to becoming a category-defining semiconductor business.”